A Study of the Patterns of Use of Etoricoxib in France (MK-0663-148)

• Status: Completed
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This postmarketing study will examine the use of etoricoxib (Arcoxia®) in routine clinical practice in France as well as the use of celecoxib (Celebrex®).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Celecoxib; Etoricoxib

Criteria

Inclusion Criteria:

• Treatment-naive, discontinued the previous treatment course of etoricoxib or celecoxib at least 3 months previously or currently receiving continuous treatment with oral etoricoxib or celecoxib

• Consent to take part in the study

• Included in his/her physician's client base for at least 1 year

Exclusion Criteria:

• Unable to receive follow-up over a year

• Included in an interventional trial